Breast Cancer News

Effect of Chemotherapy on Prometastatic Extracellular Vesicles Warrants Further Research

Effect of Chemotherapy on Prometastatic Extracellular Vesicles Warrants Further Research

Breast cancer models showed certain neoadjuvant chemotherapy promoted prometastatic behavior.

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications

Celltrion and Teva announced that the FDA has approved Herzuma (trastuzumab-pkrb) injection, a new biosimilar to Herceptin (trastuzumab; Genentech) for certain HER2-overexpressing breast cancer indications.

Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI

Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI

Researchers reported that 3 years after whole-breast irradiation and a tumor bed boost, outcomes with hypofractionation and conventional fractionation are similar.

Younger Breast Cancer Patients at Higher Risk for Osteoporosis

Younger Breast Cancer Patients at Higher Risk for Osteoporosis

Investigators found that incident osteopenia and osteoporosis are significantly higher in young survivors of breast cancer.

Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer

Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer

CARB-BC predicted grade 3 to 5 adverse events, dose modifications, and hospitalizations.

Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy

Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy

Researchers find that surgical decision making is often driven by factors beyond extent of disease.

Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment

Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment

Among breast cancer patients on adjuvant trastuzumab, lisinopril and carvedilol reduced cardiotoxicity, but only for those in the anthracycline cohort.

Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer

Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer

The immune marker PD1 may be prognostic for survival in patients with TNBC who achieve a pathologic complete response after neoadjuvant therapy.

Rates of Adverse Events Similar Regardless of IMRT Boost Type

Rates of Adverse Events Similar Regardless of IMRT Boost Type

The rates of adverse events seen across dose schedule type for patients who underwent IMRT were roughly similar.

TAILORx Shows Black Women With Breast Cancer Have Worse Clinical Outcomes

TAILORx Shows Black Women With Breast Cancer Have Worse Clinical Outcomes

Black women with the most common type of breast cancer had worse clinical outcomes compared with white women, despite receiving similar systemic therapy.

Partial-Breast Irradiation Not Equal to Whole-Breast Irradiation in Early-Stage Breast Cancer

Partial-Breast Irradiation Not Equal to Whole-Breast Irradiation in Early-Stage Breast Cancer

Partial-breast irradiation failed to meet protocol-defined measures for equivalence.

Alpelisib Plus Fulvestrant Continues to Show Improved PFS in PIK3CA-Mutant, HR+, HER2- Advanced Breast Cancer

Alpelisib Plus Fulvestrant Continues to Show Improved PFS in PIK3CA-Mutant, HR+, HER2- Advanced Breast Cancer

Alpelisib plus fulvestrant consistently resulted in prolonged PFS among patients with HR-positive, HER2-negative advanced breast cancer who also had PIK3CA mutations.

High CTC Count Favors Chemotherapy in First-Line ER+, HER2- Metastatic Breast Cancer

High CTC Count Favors Chemotherapy in First-Line ER+, HER2- Metastatic Breast Cancer

CTC count may help guide the decision between first-line chemotherapy or endocrine therapy in ER-positive, HER-negative metastatic breast cancer.

Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS

Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS

The extension of adjuvant anastrozole to 10 years of treatment showed higher rates of DFS and distant DFS, but did not improve overall survival.

Palbociclib Plus Letrozole Did Not Show Clinical Benefit in PALLET Trial

Palbociclib Plus Letrozole Did Not Show Clinical Benefit in PALLET Trial

The addition of palbociclib to letrozole did not show clinical benefit as a neoadjuvant therapy, but did enhance the suppression of malignant cell proliferation.

Low-Dose Tamoxifen Prevents Recurrence of Breast Intraepithelial Neoplasia

Low-Dose Tamoxifen Prevents Recurrence of Breast Intraepithelial Neoplasia

The results of the TAM-01 phase III trial suggest that the dose of tamoxifen can be lowered to achieve better safety without compromising efficacy.

Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo

Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo

A meta-analysis showed that breast cancer patients who have a pathologic complete response after neoadjuvant chemotherapy may not benefit from adjuvant chemotherapy.

Age, Grade, Stage Predicted Receipt of Adjuvant Chemotherapy in Elderly Patients With Breast Cancer

Age, Grade, Stage Predicted Receipt of Adjuvant Chemotherapy in Elderly Patients With Breast Cancer

Adjuvant chemotherapy was linked to improved overall survival in older adults with breast cancer.

Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial

Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial

Adjuvant trastuzumab emtansine showed improved invasive disease-free survival compared with trastuzumab in HER2-positive early breast cancer.

Mutations Identified Distinguishing Metastatic from Early-Stage HR+/HER2- Breast Cancer

Mutations Identified Distinguishing Metastatic from Early-Stage HR+/HER2- Breast Cancer

New research may help identify new candidate targets and stratify patients eligible for innovative therapies.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs